NCT00410059View on ClinicalTrials.gov

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Lung Cancer
Interventions
DRUG

Erlotinib

150 mg by mouth daily x 28 days

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER

NCT00410059 - BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | Biotech Hunter | Biotech Hunter